CLRB vs. ADAG, EBS, DMAC, IOBT, ANIX, CLSD, ORMP, BTAI, ALLK, and PMVP
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Adagene (ADAG), Emergent BioSolutions (EBS), DiaMedica Therapeutics (DMAC), IO Biotech (IOBT), Anixa Biosciences (ANIX), Clearside Biomedical (CLSD), Oramed Pharmaceuticals (ORMP), BioXcel Therapeutics (BTAI), Allakos (ALLK), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical preparations" industry.
Adagene (NASDAQ:ADAG) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
9.5% of Adagene shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 4.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Cellectar Biosciences had 2 more articles in the media than Adagene. MarketBeat recorded 6 mentions for Cellectar Biosciences and 4 mentions for Adagene. Cellectar Biosciences' average media sentiment score of 1.07 beat Adagene's score of 0.46 indicating that Adagene is being referred to more favorably in the media.
Adagene has higher revenue and earnings than Cellectar Biosciences.
Adagene currently has a consensus price target of $5.00, suggesting a potential upside of 124.22%. Cellectar Biosciences has a consensus price target of $20.00, suggesting a potential upside of 551.47%. Given Adagene's higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Adagene.
Cellectar Biosciences' return on equity of 0.00% beat Adagene's return on equity.
Adagene has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
Cellectar Biosciences received 222 more outperform votes than Adagene when rated by MarketBeat users. However, 78.26% of users gave Adagene an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
Summary
Adagene beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
